$ICPT buy opportunity for risk prone investors

Our daily analysis of a stock with a major event/upside: Intercept’s Letter Overblown

Intercept (ICPT) saw a major slump last week, falling 20% from $110 to $85 or so, after the company’s CEO Dr Mark Pruzanski sent a “Dear Doctor” letter out to prescribing physicians of its Ocaliva medication telling them not to prescribe the drug in higher doses than recommended. 

Read the full analysis in our Daily Pharma Scoop at SeekingAlpha Marketplace.